DE59310379D1 - Asparaginsäurederivate, ihre Herstellung und Verwendung - Google Patents

Asparaginsäurederivate, ihre Herstellung und Verwendung

Info

Publication number
DE59310379D1
DE59310379D1 DE59310379T DE59310379T DE59310379D1 DE 59310379 D1 DE59310379 D1 DE 59310379D1 DE 59310379 T DE59310379 T DE 59310379T DE 59310379 T DE59310379 T DE 59310379T DE 59310379 D1 DE59310379 D1 DE 59310379D1
Authority
DE
Germany
Prior art keywords
alkyl
phenyl
substd
alkoxy
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE59310379T
Other languages
English (en)
Inventor
Dr Klingler
Dr Zoller
Dr Just
Dr Jablonka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Priority to DE59310379T priority Critical patent/DE59310379D1/de
Application granted granted Critical
Publication of DE59310379D1 publication Critical patent/DE59310379D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE59310379T 1992-04-13 1993-03-18 Asparaginsäurederivate, ihre Herstellung und Verwendung Expired - Lifetime DE59310379D1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE59310379T DE59310379D1 (de) 1992-04-13 1993-03-18 Asparaginsäurederivate, ihre Herstellung und Verwendung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4212304A DE4212304A1 (de) 1992-04-13 1992-04-13 Asparaginsäurederivate, ihre Herstellung und Verwendung
DE59310379T DE59310379D1 (de) 1992-04-13 1993-03-18 Asparaginsäurederivate, ihre Herstellung und Verwendung

Publications (1)

Publication Number Publication Date
DE59310379D1 true DE59310379D1 (de) 2005-12-01

Family

ID=6456690

Family Applications (2)

Application Number Title Priority Date Filing Date
DE4212304A Withdrawn DE4212304A1 (de) 1992-04-13 1992-04-13 Asparaginsäurederivate, ihre Herstellung und Verwendung
DE59310379T Expired - Lifetime DE59310379D1 (de) 1992-04-13 1993-03-18 Asparaginsäurederivate, ihre Herstellung und Verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE4212304A Withdrawn DE4212304A1 (de) 1992-04-13 1992-04-13 Asparaginsäurederivate, ihre Herstellung und Verwendung

Country Status (15)

Country Link
US (1) US5399570A (de)
EP (2) EP0784058B8 (de)
JP (1) JP3504287B2 (de)
KR (1) KR930021605A (de)
AT (1) ATE307825T1 (de)
AU (1) AU659299B2 (de)
CA (1) CA2093770C (de)
CZ (1) CZ290280B6 (de)
DE (2) DE4212304A1 (de)
ES (1) ES2250980T3 (de)
HU (1) HU218206B (de)
IL (1) IL105355A (de)
SK (1) SK282125B6 (de)
TW (1) TW267158B (de)
ZA (1) ZA932535B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169930A (en) * 1990-01-05 1992-12-08 La Jolla Cancer Research Foundation Fibronectin receptor
DK0513675T3 (da) * 1991-05-13 1996-09-30 Fujisawa Pharmaceutical Co Hidtil ukendt peptidforbindelse samt fremgangsmåde til fremstilling deraf
TW257757B (de) * 1993-03-03 1995-09-21 Boehringer Mannheim Gmbh
US5750754A (en) * 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
PT825184E (pt) * 1993-03-29 2001-11-30 Astrazeneca Ab Derivados heterociclicos como inibidores de agregacao de plaquetas
ZW4194A1 (en) * 1993-03-29 1994-12-21 Zeneca Ltd Heterocyclic compounds
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
GB9313285D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Acid derivatives
US5463011A (en) * 1993-06-28 1995-10-31 Zeneca Limited Acid derivatives
US6274705B1 (en) * 1996-05-02 2001-08-14 Aventis Pharmaceuticals Products Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
US5446056A (en) * 1993-11-24 1995-08-29 The Du Pont Merck Pharmaceutical Company Isoxazoline compounds useful as fibrinogen receptor antagonists
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US7001921B1 (en) 1995-01-23 2006-02-21 Biogen Idec Ma Inc. Cell adhesion inhibitors
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
WO1997026250A1 (en) * 1996-01-16 1997-07-24 Merck & Co., Inc. Integrin receptor antagonists
US6239108B1 (en) 1996-07-11 2001-05-29 Biogen, Inc. Cell adhesion inhibitors
CA2261974A1 (en) 1996-07-25 1998-02-05 Biogen, Inc. Molecular model for vla-4 inhibitors
US6686350B1 (en) 1996-07-25 2004-02-03 Biogen, Inc. Cell adhesion inhibitors
US5759152A (en) * 1996-10-02 1998-06-02 Mayo Foundation For Medical Education And Research Phase-aligned NMR surface coil image reconstruction
US6458781B1 (en) * 1998-04-27 2002-10-01 David Thomas Connor Substituted diarylalkyl amides as calcium channel antagonists
CN1148350C (zh) 1998-05-28 2004-05-05 拜奥根有限公司 新型VLA-4抑制剂:oMePUPA-V
GEP20063956B (en) 1999-08-13 2006-11-10 Biogen Idec Inc Cell adhesion inhibitors
US6875743B1 (en) 2000-11-28 2005-04-05 Biogen, Inc. Cell adhesion inhibitors
DE10204789A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
AU2004275821A1 (en) * 2003-09-25 2005-04-07 Dmi Biosciences Inc. Methods and products which utilize N-acyl-L-aspartic acid
MXPA06010756A (es) * 2004-03-24 2006-12-15 Jerini Ag Nuevos compuestos para la inhibicion de la angiogenesis y su uso.
US7196112B2 (en) * 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
WO2006087232A1 (en) * 2005-02-17 2006-08-24 Instituto Del Metabolismo Celular, S.L. L-aspartic acid for the treatment of problems in connection with the fat or glucose metabolism

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879313A (en) * 1988-07-20 1989-11-07 Mosanto Company Novel platelet-aggregation inhibitors
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
JPH05500954A (ja) * 1989-09-29 1993-02-25 ローヌ―プーラン　ローラー　インターナショナル（ホウルディングス）　インコーポレイテッド 抗血栓性ペプチド及び疑似ペプチド
US5051405A (en) * 1989-10-10 1991-09-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptides and pseudopeptides
US5086069A (en) * 1990-02-05 1992-02-04 Rorer Pharmaceutical Corporation Anti-thrombotic peptide and pseudopeptide derivatives
US5264420A (en) * 1990-09-27 1993-11-23 Merck & Co., Inc. Fibrinogen receptor antagonists
EP0574545B1 (de) * 1991-03-06 1994-11-30 G.D. Searle & Co. Phenylamidinderivate als plättchenaggregationsinhibitoren
US5227490A (en) * 1992-02-21 1993-07-13 Merck & Co., Inc. Fibrinogen receptor antagonists

Also Published As

Publication number Publication date
EP0784058A1 (de) 1997-07-16
EP0565896A2 (de) 1993-10-20
JP3504287B2 (ja) 2004-03-08
HU9301071D0 (en) 1993-06-28
CA2093770A1 (en) 1993-10-14
US5399570A (en) 1995-03-21
CZ290280B6 (cs) 2002-07-17
AU659299B2 (en) 1995-05-11
HU218206B (hu) 2000-06-28
HUT64016A (en) 1993-11-29
EP0784058B1 (de) 2005-10-26
DE4212304A1 (de) 1993-10-14
ATE307825T1 (de) 2005-11-15
CA2093770C (en) 2004-09-07
KR930021605A (ko) 1993-11-22
IL105355A (en) 1998-03-10
ZA932535B (en) 1993-11-04
JPH07109256A (ja) 1995-04-25
CZ49493A3 (en) 1994-02-16
AU3683693A (en) 1993-10-14
EP0565896A3 (de) 1994-01-12
SK33493A3 (en) 1994-02-02
EP0784058B8 (de) 2005-12-28
SK282125B6 (sk) 2001-11-06
ES2250980T3 (es) 2006-04-16
TW267158B (de) 1996-01-01
IL105355A0 (en) 1993-08-18

Similar Documents

Publication Publication Date Title
DE59310379D1 (de) Asparaginsäurederivate, ihre Herstellung und Verwendung
ATE98468T1 (de) 2-aminopyrimidin-3-oxid-derivate enthaltende zusammensetzungen zur verwendung zum vermindern des haarausfalles und zum induzieren und stimulieren des haarwuchses und neue von 2aminopyrimidin-3-oxid abgeleitete verbindungen.
ATE125148T1 (de) 2,4,6-triaminopyrimidin-n-oxidderivate enthaltende zusammensetzungen zur verwendung beim vermindern des haarausfalles sowie zum auslösen und anregen des haarwuchses und neue 2,4,6- triaminopyrimidin-n-oxidderivate.
ATE165332T1 (de) Polyenderivate, diese enthaltende pharmazeutische und kosmetische zusammensetzungen und ihre verwendung
DE59309819D1 (de) Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten zur Behandlung von Erkrankungen, die durch die nichtenzymatische Glykosylierung bedingt sind
UA50725C2 (uk) Похідні 2-[(2-алкокси-6-трифторметилпіримідин-4-іл)оксиметилен]- фенілоцтової кислоти, спосіб їх отримання, застосування піримідин-4-олів для отримання цих похідних та засіб для боротьби зі шкідниками
DE69303573T2 (de) 2-Saccharinylmethyl-aryl-carboxylate-derivate als proteolytic Enzym-inhibitore und Zusammensetzungen davon und Behandlungsmethoden darauf
EP0205299A3 (de) Isatinderivate, diese enthaltende Zusammensetzungen und deren Anwendung gegen Geschwüre
AU609377B2 (en) New derivaties of 4-OH quinoline carboxylic acid substituted in position 2 by a possibly etherified or esterified dihydroxyl group, the process and intermediates for preparation, their application as medicaments and the compositions containing them
DK0864561T3 (da) Benzensulfonylamin-derivater, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger indeholdende sådanne derivater
FI922268A (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten N-difenyylialkyylialkoksisubstituoitujen 3-piperidiinikarboksyylihappojohdannaisten valmistamiseksi
ATE229495T1 (de) Verfahren zur herstellung von n-acyl- aminosäureestern und n-acyl-aminoacetalen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, 65929 FRANKFURT,

8364 No opposition during term of opposition